Brendan joined Xalud Therapeutics after an accomplished 17-year career at Pfizer with roles of increasing responsibility in finance, strategy, commercial, and operations. Most recently, he served as the general manager of Greenstone LLC, the top authorized generics company in the United States. He redefined the growth potential for this billion-dollar division of Pfizer and was responsible for the sales, customer support, marketing, and business development functions. Prior to this, Brendan led strategy and commercial operations for an $11 billion business in Pfizer Essential Health and had key roles in corporate finance and business leadership during Pfizer’s transformation over the last decade. Before Pfizer, Brendan held business advisory roles at Deloitte & Touche and Arthur Andersen. Brendan is a CFA and a CPA, and he holds an MBA from the Frank Zarb School of Business at Hofstra University.
.svg)
